The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings

Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO).

Over time the two companies plan to focus on Voltron’s VaxCelerate vaccine platform’s effectiveness and utility in a variety of tumor settings. The mutual effort is designed to evaluate several development and regulatory strategies, including pre-clinical work, indication/patient population selection, trial site selection and supporting Voltron’s initial BLA submission.

“Voltron is excited to have forged a relationship with TD2 to best leverage and develop our novel vaccine platform, VaxCelerate. We believe TD2’s wide ranging expertise in oncology, from trial design and execution to regulatory strategy across all cancer types, will help Voltron create differentiating data to bring more effective treatments to market in less time. Our highly experienced operations team was instrumental in the selection process and was extremely impressed with TD2’s capabilities, track record and responsiveness. Our initial project will focus on VaxCelerate in the ovarian cancer setting with additional consideration being given to potential future opportunities in NSCLC, pancreatic cancer, head and neck cancer and mesothelioma,” said Pat Gallagher, Managing Partner at LVP and CEO of Voltron.

“TD2 is honored to be selected to work with the great team at Voltron to accelerate this novel self-assembling vaccine medicine to help patients with ovarian and other cancers,” said Stephen Gately, CEO at TD2. “We look forward to deploying our full translational oncology service offerings to support all needed aspects of development with a key focus on the clinical and regulatory strategy to select patients most likely to gain clinical benefit.”

“It continues to be an exciting time of growth for Laidlaw Venture Partners, and in particular, our portfolio company Voltron Therapeutics. In past months, we have announced the addition of numerous world class healthcare professionals to our team. Today’s Voltron news is a result of leveraging that team’s experience, varied skill sets and invaluable relationships forged over decades of specialized work in the medical field,” said James Ahern, Founding Partner, Laidlaw Venture Partners.

Climbing the Mountain: Current Challenges in Early Phase Oncology Clinical Trials

Oncology clinical trials are at the forefront of medical research, paving the way for innovative treatments and advancements in the fight against...

Read more +

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

Cell therapy has emerged as a promising approach in the field of cancer treatment, and chimeric antigen receptor (CAR) T-cell therapy has shown...

Read more +

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

The dynamic field of cancer research is continually evolving, driven by the pursuit of deeper understanding and novel therapeutic strategies against...

Read more +


Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.

Skip to content